Latest Technology Platforms News

Camplify Holdings reported a $15.8 million net loss for FY25 amid strategic consolidation and tech integration, while launching its MyWay membership model to drive future profitability.

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

Life360, Inc. reported robust Q3 2025 financial results driven by subscription and partnership revenue growth, alongside a leadership transition and strategic capital moves. The company also announced a major acquisition to bolster its advertising platform.

X2M Connect has secured over half a million Australian dollars in new and repeat water digitisation contracts in South Korea, driving strong early revenue growth in FY26. These deals expand the company’s footprint across thousands of households and highlight growing government adoption of IoT solutions.

Proteomics International secures half a million dollars from the Western Australian Government to accelerate commercialisation of PromarkerEndo, a groundbreaking blood test for early endometriosis diagnosis.

Cluey Ltd announces a strategic acquisition of tutoring provider Art of Smart, backed by a fully underwritten $4.5 million entitlement offer. The deal aims to expand Cluey’s omnichannel learning services and drive scalable growth.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

Linius Technologies has implemented a sweeping operational restructure, cutting expenses by more than 60% compared to FY25, while progressing a pivotal proof of concept with a major European football league and securing over $3.7 million in new funding.

Mad Paws Holdings reported a robust September quarter with 14% revenue growth and a successful divestment of Pet Chemist, while advancing its acquisition scheme with Rover Group.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Catapult Sports has completed its acquisition of IMPECT GmbH, a leader in soccer scouting analytics, enhancing its technology suite with proprietary data insights.

Humm Group reports a 14% decline in new loan originations for 1Q26, driven by a steep 61% fall in Australian Point of Sale volumes following regulatory changes and technology setbacks. However, international growth and asset expansion provide some offset.